Physician profile
Damien H Mitchell
NPI 1144410556
$1,535.44
in general payments reported to CMS, 2019-2025
19 companies · $714 in 2025
The $714 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.64 · 2020: $91.74 · 2021: $76.18 · 2022: $191 · 2023: $205 · 2024: $204 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $329.21 | 2021-2025 | |
| Corium, LLC | $216.59 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $175.59 | 2022-2025 | Qelbree |
| Tris Pharma INC | $132.74 | 2020-2025 | Onyda Xr |
| Pfizer INC. | $117.36 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $81.44 | 2024-2025 | |
| Cranial Technologies, INC | $75.35 | 2023-2025 | Doc Band |
| Sobi, INC | $63.65 | 2020-2022 | |
| Glaxosmithkline, LLC. | $55.25 | 2021-2025 | Bexsero, Pediarix, Penmenvy |
| Genentech USA, INC. | $52.64 | 2019 | |
| Kaleo, INC. | $42.72 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $37.82 | 2024 | Dupixent |
| Seqirus USA INC | $30.13 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $29.14 | 2025 | Neffy |
| Ironshore Pharmaceuticals INC. | $25.70 | 2023 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.64 | 2023 | Vpriv |
| Kyowa Kirin, INC. | $17.64 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $15.79 | 2025 | Vaxneuvance, Vaxelis, Enflonsia |
| Adlon Therapeutics L.P. | $15.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damien Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.